Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates.

[1]  J. Klein,et al.  Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. , 2007, Blood.

[2]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[3]  M. Labopin,et al.  Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Grou , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Rezvani,et al.  Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. , 2006, Blood.

[5]  M. Horowitz,et al.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. , 2005, Blood.

[6]  A. Elmaagacli,et al.  Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. , 2005, Blood.

[7]  S. Forman,et al.  Development of a multiplex PCR-SSP method for Killer-cell immunoglobulin-like receptor genotyping. , 2004, Tissue antigens.

[8]  S. Sohn,et al.  Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Appelbaum,et al.  Thomas' hematopoietic cell transplantation , 2003 .

[10]  J. Miguel,et al.  Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. , 2003, Blood.

[11]  Franco Locatelli,et al.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. , 2003, Blood.

[12]  R. Gale,et al.  Decreased treatment failure in recipients of HLA‐identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses , 2003, British journal of haematology.

[13]  J. Bourhis,et al.  Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation , 2003, Leukemia.

[14]  F. Frassoni,et al.  Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. , 2002, Blood.

[15]  Daniel J Weisdorf,et al.  Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. , 2002, Blood.

[16]  P. Sun,et al.  A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. , 2002, Molecular immunology.

[17]  S. Chevret,et al.  Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. , 2002, Blood.

[18]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[19]  S. Heimfeld,et al.  CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. , 2001, Blood.

[20]  O. Olerup,et al.  HLA-AB typing by polymerase-chain reaction with sequence-specific primers: more accurate, less errors, and increased resolution compared to serological typing. , 2001, Tissue antigens.

[21]  R. Altemus,et al.  Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell‐depleted peripheral blood stem cell transplants with delayed donor lymphocyte add‐back , 2001, British journal of haematology.

[22]  M. Remberger,et al.  No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. , 2001, Blood.

[23]  N. Ueno,et al.  Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. , 1999, Blood.

[24]  直子 加藤,et al.  Graft-Versus-host Disease , 1999 .

[25]  P Parham,et al.  Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. , 1997, Journal of immunology.

[26]  R Storb,et al.  Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. , 1997, Blood.

[27]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[28]  P. Parham,et al.  The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor , 1995, The Journal of experimental medicine.

[29]  D. Niederwieser,et al.  Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT) , 1987, British journal of haematology.

[30]  W. Hauck,et al.  Wald's Test as Applied to Hypotheses in Logit Analysis , 1977 .

[31]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[33]  A. Barrett,et al.  Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation , 1997, Annals of Hematology.

[34]  C. Dunbar,et al.  CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. , 1996, Blood.

[35]  R. Peto,et al.  Asymptotically efficient rank invariant test procedure (with discussion). , 1972 .

[36]  D.,et al.  Regression Models and Life-Tables , 2022 .